Detailed Meeting Agenda
Wednesday, 7th September
| 15:00-18:00 |
Registration, Poster Set Up |
Thursday, 8th September
| 08:00-09:00 |
Registration, Poster Set Up (Please note that The Royal Library opens at 08:00) |
| 09:00-09:15 |
Welcome and Opening Remarks |
| |
Gunther Hartmann, MD, PhD, Universitätsklinikum Bonn, OTS President |
| 09:15-10:30 |
Session 1: Hot Topics: Short Talks Selected from Abstracts |
| |
Chair: Gunther Hartmann, MD, PhD, Universitätsklinikum Bonn |
| 09:15-09:30 |
Expanding the Structural Diversity Repertoire of siRNA's |
| |
Dong-ki Lee, PhD, Sungkyunkwan University |
| 09:30-09:45 |
Activation of RNA Interferance in Animals with Single Stranded Oligonucleotides |
| |
Eric Swayze, PhD, ISIS Pharmaceuticals |
| 09:45-10:00 |
Limitations for RNAi: intracellular release of siRNA and cell stress |
| |
Georg Sczakiel, PhD, Institute for Molecular Medicine, University of Lübeck |
| 10:00-10:15 |
Preclinical Efficacy and Safety of Phosphorodiamidate Morpholino Oligomers (PMO) |
| |
Peter Sazani, PhD, AVI BioPharma, Inc. |
| 10:15-10:30 |
5'-triphosphate dsRNA-induced stimulation of RIG-I prevents influenza H1N1 infection of primary nasal epithelial cell culture and protects mice from infection in vivo |
| 10:30-11:00 |
Refreshment Break |
| 11:00-12:30 |
Session 2: Nucleic Acid Chemistry |
| |
Chair: Jesper Wengel, PhD, University of Southern Denmark, Odense |
| 11:00-11:30 |
Nucleotide Chemistry and Gene Silencing |
| |
Jesper Wengel, PhD, University of Southern Denmark, Odense |
| 11:30-12:00 |
Arabinose Modified Antisense and siRNAs: Biological Applications, Structural Considerations, and Delivery Strategies |
| |
Masad J. Damha, PhD, McGill University, Montreal |
| 12:00-12:30 |
siRNA Activity, Stability and 3D-Structural Properties of 2'-Fluoro RNA and GNA |
| |
Martin Egli, PhD, Vanderbilt University Medical Center, Nashville |
| 12:30-14:00 |
Lunch and Attended Poster Session |
| 12:30-13:15 |
Standing Lunch Buffet |
| 13:15-14:00 |
Attended Poster Session |
| 14:00-14:30 |
Keynote Session: Oligonucleotide Therapeutics reviewed in memory of Dr. Alan Gewirtz |
| |
Keynote Speaker: Fritz Eckstein, PhD, Max-Planck-Institute for Experimental Medicine, Göttingen |
| 14:30-16:00 |
Session 3: RNA Biology: New Frontiers |
| |
Chair: Mark Kay, MD, PhD, Stanford University |
| 14:30-15:00 |
Primary microRNA Function in Target Recognition and Repression |
| |
Chang-Zheng Chen, PhD, Stanford University |
| 15:00-15:30 |
Regulation of small RNA function |
| |
Gunter Meister, PhD, University of Regensburg and Max-Planck-Institute of Biochemistry, Munich |
| 15:30-16:00 |
The mechanism of miRNA and siRNA Argonaute loading in mammals |
| |
Mark Kay, MD, PhD, Stanford University |
| 16:00-16:30 |
Refreshment Break |
| 16:30-18:00 |
Session 4: Delivery of Nucleic Acids |
| |
Chair: Jean-Jacques Toulmé, PhD, INSERM, University of Bordeaux, Paris |
| 16:30-17:00 |
Chemical Strategies for Delivery of RNAi Drugs |
| |
Muthiah Manoharan, PhD, Alnylam Pharmaceuticals |
| 17:00-17:30 |
Non covalent peptide-based delivery systems |
| |
Gilles Divita, PhD, Centre de Recherches de Biochimie Macromoléculaire, Department of Molecular Biophysics and
Therapeutics, Montpellier |
| 17:30-18:00 |
Investigating the Potential of Therapeutic Oligonucleotides for Pulmonary Diseases |
| |
Ken Clark, GlaxoSmithKline |
| 18:00-19:30 |
Welcome Reception with Attended Posters |
| 19:30 |
Meet the Experts |
Friday, 9th September
| 08:00 |
Registration Opens (Please note that The Royal Library opens at 08:00) |
| |
|
| 08.30-10:00 |
Session 5: Immunobiology of Nucleic Acids |
| |
Chair: Art Krieg, MD, Atlas Venture |
| 08:30-09:00 |
RIG-I and tolerance of self-RNA |
| |
Gunther Hartmann, MD, PhD, Universitätsklinikum Bonn |
| 09:00-09:30 |
Regulation of the Innate Immune Response Using Oligonucleotide-based Inhibitor of Toll-Like Receptors (TLR) |
| |
Franck Barrat, PhD, Dynavax Technologies |
| 09:30-10:00 |
Intracellular trafficking of TLR ligands in human plasmacytoid dendritic cells |
| |
Patricia Fitzgerald-Bocarsly, PhD, UMDNJ -- New Jersey Medical School |
| 10:00-10:30 |
Refreshment Break |
| 10:30-12:00 |
Session 6: Targeting Coding RNA |
| |
Chair: David Corey, PhD, UT Southwestern Medical Center, Dallas |
| 10:30-11:00 |
Gymnotic Delivery of Antisense Oligonucleotides |
| |
Cy Stein, MD, PhD, Albert Einstein College of Medicine, Bronx |
| 11:00-11:30 |
Modulation of Gene Expression by Oligonucleotide Chemistry-Dependent Recruitment of Proteins to RNA Transcripts |
| |
Frank Rigo, PhD, Isis Pharmaceuticals |
| 11:30-12:00 |
Clinical development of mipomersen |
| |
Erik Stroes, MD, PhD, AMC Research Institute, Amsterdam |
| 12:00-13:30 |
Lunch with Attended Poster Session |
| 12:00-12:45 |
Standing Lunch Buffet |
| 1245-13:30 |
Attended Poster Session |
| 13:30-15:00 |
Session 7: Targeting microRNA |
| |
Chair: Markus Stoffel, MD, PhD, ETH Zurich |
| 13:30-14:00 |
Therapeutic Targeting of microRNAs |
| |
Neil Gibson, PhD, Regulus Therapeutics |
| 14:00-14:30 |
Therapeutic targeting of individual cardiac cell types by miRNA antagonists |
| |
Thomas Thum, MD, PhD, Integrated Research Center, Medical School Hannover, Germany |
| 14:30-15:00 |
Oncomir-1 in cancer and development: a tale of mice and men |
| |
Andrea Ventura, MD, PhD, Sloan-Kettering Institute, New York |
| 15:00-15:30 |
Refreshment Break |
| 15:30-17:00 |
Session 8: Targeting Liver and Tumors |
| |
Chair: Henrik Ørum, PhD, Santaris Pharma a/s |
| 15:30-16:00 |
Evaluation of locked nucleic acid (LNA)-based mRNA antagonists in cancer patients |
| |
Aby Buchbinder, Enzon Pharmaceuticals |
| 16:00-16:30 |
ALN-TTR, an RNAi Therapeutic for the Treatment of Transthyretin Amyloidosis |
| |
Dinah Sah, PhD, Alnylam Pharmaceuticals |
| 16:30-17:00 |
Targeting miRNA-122 for the Treatment of HCV |
| |
Henrik Ørum, PhD, Santaris Pharma a/s |
| 17:15-19:15 |
Exhibitor Reception at the Børsen |
Saturday, 10th September
| 08:00 |
Registration Opens (Please note that The Royal Library opens at 08:00) |
08:15-09:45
|
Session 9: Targeting Infection |
| |
Chair: John Rossi, PhD, City of Hope, Duarte, California |
| 08:15-08:45 |
The development of aptamers as candidate antiviral agents: towards a polyvalent microbicide |
| |
William James, PhD, Sir William Dunn School of Pathology, University of Oxford |
| 08:45-09:15 |
Developing the next generation of expressed RNAi modalities against rapidly-evolving viral infections |
| |
Marc Weinberg, PhD, University of the Witwatersrand Medical School, Parktown |
| 09:15-09:45 |
Dual function therapeutic Aptamer siRNA combinations |
| |
John Rossi, PhD, City of Hope, Duarte, California |
| 09:45-11:15 |
Session 10: Targeting the Central Nervous System -- Sponsored by International Society of Neurochemistry |
| |
Chair: Hermona Soreq, PhD, The Hebrew University of Jerusalem |
| 09:45-10:15 |
Systematic versus CNS Delivery of MOE Antisense Oligonucleotide to Correct Defective Splicing in a Severe Mouse Model of Spinal Muscular Atrophy |
| |
Adrian Krainer, PhD, Cold Spring Harbor Laboratory |
| 10:15-10:45 |
Micro-RNAs in the Neuroimmune Interface: From Inflammation to Lethal Poisoning Protection |
| |
Hermona Soreq, PhD, The Hebrew University of Jerusalem |
| 10:45-11:15 |
The Role of microRNA in Regulating the Central Stress Response |
| |
Alon Chen, PhD, MBA, Weizmann Institute of Science, Rehovot, Israel |
| 11:15-11:45 |
Refreshment Break |
11:45-13:15
|
Session 11: Targeting Genetic Diseases |
| |
Chair: Dieter Gruenert, PhD, University of California, San Francisco |
| 11:45-12:15 |
Exploring and exploiting designer nucleases for targeted genome engineering |
| |
Toni Cathomen, PhD, Hannover Medical School |
| 12:15-12:45 |
Oligonucleotide-directed gene modification in mouse Embryonic Stem Cells to study variants of cancer-related genes |
| |
Hein te Riele, PhD, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital |
| 12:45-13:15 |
siDNA, a new strategy for inhibiting DNA repair pathways |
| |
Marie Dutriex, PhD, Institut Curie, Centre Universitaire, Orsay |
13:15
|
Closing Session - End of Conference
|
|
|
|
